Neurizon Therapeutics Ltd (NUZ)

Sydney


Symbol		Exchange		Currency
NUZ	·	Sydney	·	AUD	Delayed
ECQ0	·	Frankfurt	·	EUR	Delayed

Currency in AUD

0.057

-0.001(-1.72%)

Delayed Data·22:51:17

Fair Value

Unlock Value

Day's Range

0.057

52 wk Range

0.055

0.165

NUZ Income Statement

Assess the Neurizon Therapeutics income statement, providing a detailed view of the company’s financial performance across activities. This statement outlines key financial figures such as revenue, expenses, operating income, and net income. Assess the NUZ net worth.

Period Ending:

2017

30/06

2018

30/06

2019

30/06

2020

30/06

2021

30/06

2022

30/06

2023

30/06

2024

30/06

2025

30/06

2026

30/06

Total Revenues

aa.aa

4.51

0.87

0.84

1.54

17.77

Total Revenues Growth

aa.aa

+23.33%

-80.63%

-3.66%

+82.7%

+1,055.49%

Cost Of Revenues

aa.aa

0.31

Gross Profit

aa.aa

4.2

0.87

0.84

1.54

17.77

Gross Profit Growth

aa.aa

+22.27%

-79.18%

-3.66%

+82.7%

+1,055.49%

Gross Profit Margin %

aa.aa

93.03%

100%

Other Operating Expenses, Total

aa.aa

5.82

2.52

6.66

18.48

27.76

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+23.62%	-56.64%	+164.05%	+177.47%	+50.23%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	0.76	1.03	3.85	11.68	21.05
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	4.74	1.49	2.81	6.8	6.7
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-

Operating Income

aa.aa

-1.62

-1.65

-5.82

-16.94

-9.99

Operating Income Growth

aa.aa

-27.27%

-1.72%

-252.95%

-191.18%

+41.04%

EBIT Margin %

aa.aa

-35.92%

-188.64%

-691.08%

-1,101.41%

-56.2%

Net Interest Expenses

aa.aa

-0.09

0.08

0.02

0.34

-0.74

Net Interest Expenses Growth

aa.aa

-36.89%

+186.3%

-67.77%

+1,306.74%

-314.19%

Interest Expense, Total

aa.aa

-0.09

-0.74

Interest And Investment Income

aa.aa

0.08

0.02

0.34

Other Non Operating Expenses, Total

aa.aa

EBT, Excl. Unusual Items

aa.aa

-1.71

-1.57

-5.79

-16.59

-10.72

Gain (Loss) On Sale Of Assets

aa.aa

Other Unusual Items, Total

aa.aa

-3.11

EBT, Incl. Unusual Items

aa.aa

-1.71

-1.57

-8.9

-16.59

-10.72

EBT, Incl. Unusual Items Growth

aa.aa

-27.73%

+7.96%

-466.09%

-86.45%

+35.38%

EBT, Incl. Unusual Items Margin

aa.aa

-37.87%

-179.95%

-1,057.36%

-1,079.02%

-60.35%

Income Tax Expense

aa.aa

Net Income to Company

aa.aa

-1.71

-6.21

-7.67

-16.59

-10.72

Minority Interest

aa.aa

Net Income

aa.aa

-1.71

-6.21

-7.67

-16.59

-10.72

Net Income Growth

aa.aa

-27.73%

-263.63%

-23.53%

-116.26%

+35.38%

Net Income Margin %

aa.aa

-37.87%

-710.99%

-911.61%

-1,079.02%

-60.35%

Preferred Dividend and Other Adjustments

aa.aa

Net Income to Common Excl. Extra Items

aa.aa

-1.71

-1.57

-8.9

-16.59

-10.72

Basic EPS - Continuing Operations

aa.aa

-0.01

-0

-0.02

-0.03

-0.02

Basic EPS - Continuing Operations Growth

aa.aa

-27.27%

+9.15%

-390.12%

-41.85%

+48.3%

Diluted EPS - Continuing Operations

aa.aa

-0.01

-0

-0.02

-0.03

-0.02

Diluted EPS - Continuing Operations Growth

aa.aa

-27.27%

+9.11%

-389.92%

-41.85%

+48.3%

Basic Weighted Average Shares Outstanding

aa.aa

316.88

321.01

370.81

487.39

609.26

Diluted Weighted Average Shares Outstanding

aa.aa

316.88

321.01

370.81

487.39

609.26

Dividend Per Share

aa.aa

Dividend Per Share Growth

aa.aa

EBITDA

aa.aa

-1.45

-1.32

-5.82

-16.94

-9.98

EBITDA Growth

aa.aa

-31.02%

+9.06%

-340.04%

-191.26%

+41.06%

EBITDA Margin %

aa.aa

-32.22%

-151.27%

-690.89%

-1,101.4%

-56.18%

EBIT

aa.aa

-1.62

-1.65

-5.82

-16.94

-9.99

* In Millions of AUD (except for per share items)

FAQ

What was Neurizon Therapeutics’s revenue at year end?

At the end of the last reported fiscal year, Neurizon Therapeutics (NUZ) recorded total revenue of 17.770 million AUD.

How much revenue did Neurizon Therapeutics report in the most recent quarter?

In its most recent quarterly earnings report, Neurizon Therapeutics posted revenue of 5.973 million AUD.

What was Neurizon Therapeutics’s net income for the year?

For the full year, Neurizon Therapeutics reported net income of -10.723 million AUD.

How much net income did Neurizon Therapeutics post in the last quarter?

In the most recent quarter, Neurizon Therapeutics (NUZ) posted net income of -5.537 million AUD.

What was Neurizon Therapeutics’s gross profit for the year?

Gross profit for the year was reported at 17.770 million AUD.

How much gross profit did Neurizon Therapeutics generate last quarter?

Neurizon Therapeutics recorded gross profit of 5.973 million AUD in its latest quarterly report.

What was Neurizon Therapeutics’s annual operating income?

For the full year, Neurizon Therapeutics (NUZ) reported operating income of -9.986 million AUD.

What was Neurizon Therapeutics’s operating income last quarter?

Quarterly operating income was -5.434 million AUD.

What was Neurizon Therapeutics’s quarterly EBITDA?

In the latest quarter, EBITDA was reported at -5.434 million AUD.

What was the quarter-over-quarter change in EBITDA for Neurizon Therapeutics?

EBITDA changed by 42.405% million AUD compared to the last quarter.

What is Neurizon Therapeutics’s most recent net income margin?

Net income margin based on recent financials is -92.705% million AUD.

What is Neurizon Therapeutics’s most recent EBIT margin?

Neurizon Therapeutics reported an EBIT margin of -90.980% million AUD based on current figures.

How did Neurizon Therapeutics’s revenue change compared to the previous quarter?

Revenue changed by 93,273.472% million AUD compared to the prior quarter.

What was the quarter-over-quarter change in gross profit for Neurizon Therapeutics?

In the latest quarter, gross profit changed by 93,273.472% million AUD from the previous quarter.

S&P/TSX

36,813.65

-143.98

-0.39%

S&P/TSX 60

2,157.92

-8.56

-0.40%

US 30

53,656.00

+191.4

+0.36%

US 500

7,714.20

+38.4

+0.50%

S&P 500 VIX

15.21

-0.24

-1.55%

DAX

26,285.96

+19.82

+0.08%

Dollar Index

99.073

-0.016

-0.02%

Market Movers

Name	Last	Chg. %	Vol.
Canadian Natural	68.93	+0.36%	16.37M
Manulife Financial	59.97	+0.44%	13.05M
RBC	288.11	+0.52%	2.67M
National Bank of Canada	213.18	-4.20%	3.27M
Bank of Montreal	239.97	+0.01%	2.79M
Bank of Nova Scotia	129.81	+0.84%	4.62M
ARC Resources	33.43	-0.36%	12.07M

Name	Last	Chg. %	Vol.
VR Resources	0.4000	+233.33%	14.94M
Pharmadrug	0.01	+200.00%	14.61K
Lanebury Growth Capital	0.15	+200.00%	1.00K
Everkind	0.84	+141.35%	20.00K
Green Scientific Labs Holdings	0.06	+120.00%	15.00K
Aurora Solar Technologies	0.0100	+100.00%	15.28K
EnviroMetal Technologies	0.01	+100.00%	15.00K

Name	Last	Chg. %	Vol.
Vision Marine Technologies	0.76	-90.00%	0.00
Global Health Clinics	0.055	-80.00%	500.00
Impact Dev	0.02	-57.14%	1.64K
iAnthus Capital	0.01	-50.00%	196.48K
Molecule Holdings	0.005	-50.00%	20.11K
InsuraGuest Technologies	0.0050	-50.00%	1.50K
Albert Labs International	0.005	-50.00%	1.00K

Trending Stocks

Name	Last	Chg. %	Vol.
Bank of Nova Scotia	129.81	+0.84%	4.62M
National Bank of Canada	213.18	-4.20%	3.27M
Toronto Dominion Bank	165.87	+0.68%	2.38M
Celestica Inc.	426.16	+0.61%	183.47K
Bank of Montreal	239.97	+0.01%	2.79M

Most Undervalued Stocks

Name	Last	Upside	Fair Value
A Aaaa Aa	33.78	+60.83%	54.33
Aaaaaaaaaaaaaa Aaa	120.08	+54.74%	185.81
Aaaaa Aaaaaaa A	5.52	+47.84%	8.16
Aaaaaa A Aaaaa	9.03	+47.65%	13.33
A A Aaa A	29.49	+47.37%	43.46
Aaaaaaa Aaa A	101.55	+47.33%	149.61
Aaaaaaa	21.18	+43.62%	30.42

Name	Last	Upside	Fair Value
A Aaaa Aa	33.78	+60.83%	54.33
Aaaaaaaaaaaaaa Aaa	120.08	+54.74%	185.81
Aaaaa Aaaaaaa A	5.52	+47.84%	8.16
Aaaaaa A Aaaaa	9.03	+47.65%	13.33
A A Aaa A	29.49	+47.37%	43.46
Aaaaaaa Aaa A	101.55	+47.33%	149.61
Aaaaaaa	21.18	+43.62%	30.42

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Popular Searches

Please try another search

Neurizon Therapeutics Ltd (NUZ)

NUZ Income Statement

FAQ

What was Neurizon Therapeutics’s revenue at year end?

How much revenue did Neurizon Therapeutics report in the most recent quarter?

What was Neurizon Therapeutics’s net income for the year?

How much net income did Neurizon Therapeutics post in the last quarter?

What was Neurizon Therapeutics’s gross profit for the year?

How much gross profit did Neurizon Therapeutics generate last quarter?

What was Neurizon Therapeutics’s annual operating income?

What was Neurizon Therapeutics’s operating income last quarter?

What was Neurizon Therapeutics’s quarterly EBITDA?

What was the quarter-over-quarter change in EBITDA for Neurizon Therapeutics?

What is Neurizon Therapeutics’s most recent net income margin?

What is Neurizon Therapeutics’s most recent EBIT margin?

How did Neurizon Therapeutics’s revenue change compared to the previous quarter?

What was the quarter-over-quarter change in gross profit for Neurizon Therapeutics?

Trending Stocks